SCHEMBL29662906

SCHEMBL29662906

CCN(CC)c1ccc2c(-c3ccccc3S(=O)(=O)[O-])c3ccc(=[N+](CC)CC)cc-3oc2c1

nearest known ligand 0.82

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.82
▸ USP2 O75604 1/20 0.82
▸ POLB P06746 1/20 0.82
▸ PPARG P37231 1/20 0.82
▸ BLM P54132 1/20 0.82
▸ KMT2A Q03164 1/20 0.82
▸ RXFP1 Q9HBX9 1/20 0.82
▸ NCOR2 Q9Y618 1/20 0.82
▸ CHRM1 P11229 1/20 0.53
▸ AVPR2 P30518 3/20 0.50
▸ FPR2 P25090 4/20 0.49
▸ TGM2 P21980 1/20 0.46
▸ SLC6A4 P31645 5/20 0.45
▸ SLC6A2 P23975 3/20 0.45
▸ SLC6A3 Q01959 3/20 0.45
▸ APLNR P35414 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19962197 1.00 MEN1 (0.82) MEN1USP2POLBPPARGBLM
SCHEMBL19296594 0.91 MEN1 (0.70) MEN1USP2POLBPPARGBLM
SCHEMBL27449932 0.90 MEN1 (0.83) MEN1USP2POLBPPARGBLM
SCHEMBL16593265 0.90 MEN1 (1.00) MEN1USP2POLBPPARGBLM
SCHEMBL29355331 0.90 MEN1 (1.00) MEN1USP2POLBPPARGBLM
Water SCHEMBL7715721 0.89 MEN1 (0.98) MEN1USP2POLBPPARGBLM
SCHEMBL31011003 0.88 MEN1 (0.87) MEN1USP2POLBPPARGBLM
SCHEMBL29352150 0.88 MEN1 (0.87) MEN1USP2POLBPPARGBLM
SCHEMBL31011004 0.88 MEN1 (0.87) MEN1USP2POLBPPARGBLM
SCHEMBL29356182 0.88 MEN1 (0.87) MEN1USP2POLBPPARGBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000993-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME BLINKBIO INC (US) 2023-01-05 — — US disclosed
US-11497757-B2 Silanol based therapeutic payloads BLINKBIO, INC. (US) 2022-11-15 — — US disclosed
US-20220184104-A1 SILANOL BASED THERAPEUTIC PAYLOADS BLINKBIO INC (US) 2022-06-16 — — US disclosed
US-11291731-B2 Silicon based drug conjugates and methods of using same BLINKBIO, INC. (US) 2022-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11497757-B2 Silanol based therapeutic payloads CD47, CD4, BST2 MEN1 2446/4885USP2 1953/4885POLB 2465/4885
US-11291731-B2 Silicon based drug conjugates and methods of using same CD44, MSN, AS3MT MEN1 380/4885USP2 735/4885POLB 3269/4885
US-20230000993-A1 SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME CD44, MSN, AS3MT MEN1 380/4885USP2 735/4885POLB 3269/4885
US-20220184104-A1 SILANOL BASED THERAPEUTIC PAYLOADS CD47, CD4, BST2 MEN1 2446/4885USP2 1953/4885POLB 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback